Classification
Compound class	Synthetic organic
Approved drug?	Yes (FDA (2019))

International Nonproprietary Names
INN number	INN
10209	upadacitinib

Synonyms

ABT-494 | Rinvoq®

Comments

Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity [4,9]. The chemical structure is claimed as compound 1 in Abbvie's patent WO2015061665 [9]. It is being investigated for clinical efficacy in autoimmune diseases including rheumatoid arthritis and Crohn's disease.

Database Links
GtoPdb PubChem SID	315661321
PubChem CID	58557659
Search Google for chemical match using the InChIKey	WYQFJHHDOKWSHR-MNOVXSKESA-N
Search Google for chemicals with the same backbone	WYQFJHHDOKWSHR
Search PubMed clinical trials	upadacitinib
Search PubMed titles	upadacitinib
Search PubMed titles/abstracts	upadacitinib
Search UniChem for chemical match using the InChIKey	WYQFJHHDOKWSHR-MNOVXSKESA-N
Search UniChem for chemicals with the same backbone	WYQFJHHDOKWSHR